title: [Effects of progesterone and progestin on expression of regulated on activation, normal T cell expressed and secreted in eutopic endometrium from patients with endometriosis].
abstract: OBJECTIVE
  To investigate the effects of progesterone and progestin on the expressions of regulated on activation, normal T cell expressed and secreted (RANTES) in eutopic endometrium from patients with endometriosis.
  
  
  METHODS
  We collected the samples of endometrium from patients with endometriosis before operation or after insertion of levenorgestrel releasing intrauterine system (LNG-IUS), administration of oral medroxyprogesterone (MPA), or injection of gonadotrophic hormone releasing hormone agonist (GnRHa). Reverse transcription-polymerase chain raction was used to assay the expression of RANTES mRNA. On the other hand, progesterone (Po) and tumor necrosis factor-alpha (TNFalpha) of different concentrations and different manners were used to treat cultured cells in vitro. RANTES secretion was evaluated in the culture medium using ELISA. In order to evaluate the effect of Po on the secretion of RANTES under stimulation of TNFalpha, the cells were cultured in medium containing 100 U/ml TNFalpha and Po of different concentrations for 24 hours. After the pretreatment of Po for 48 hours at different concentrations, TNFalpha (100 U/ml, 16 h) was added to observe whether Po inhibits RANTES or not.
  
  
  RESULTS
  The expression of RANTES mRNA in eutopic endometrium of patients with endometriosis was significantly higher than in control group (28.0 +/- 9.0 vs. 22.0 +/- 5.6, P < 0.05). Following the exposures to LNG-IUS (24.0 +/- 4.2 vs. 25.9 +/- 4.2, P > 0.05) or GnRHa (23.0 +/- 12.9 vs. 26.9 +/- 5.2, P > 0.05), the expression of RANTES mRNA had no change. MPA significantly increased the expression of RANTES mRNA (42.6 +/- 3.1 vs. 24.3 +/- 5.7, P < 0.05). Po itself had no significant effect on the secretion of RANTES. Stimulated by Po and TNFalpha at the same time, the secretion of RANTES significantly increased. After pretreatment with Po for 48 hours, the reaction of RANTES to the stimulating effect of TNFalpha was down-regulated.
  
  
  CONCLUSIONS
  The eutopic endometrium of patients with endometriosis has high chemotactic activity. It may be feasible to prevent and treat endometriosis with progestins.
authors.affiliation: Department of Obstetrics and Gynecology, PUMC Hospital, CAMS and PUMC, Beijing 100730, China.
authors.forename: Shan
authors.initials: S
authors.lastname: Deng
authors.forename: Yi
authors.initials: Y
authors.lastname: Dai
authors.forename: Jing-He
authors.initials: JH
authors.lastname: Lang
authors.forename: Jin-Hua
authors.initials: JH
authors.lastname: Leng
authors.forename: Zhu-Feng
authors.initials: ZF
authors.lastname: Liu
authors.forename: Da-Wei
authors.initials: DW
authors.lastname: Sun
authors.forename: Lan
authors.initials: L
authors.lastname: Zhu
authors.forename: Xian-Jie
authors.initials: XJ
authors.lastname: Tan
mesh_terms: D002478:Cells, Cultured; D018946:Chemokine CCL5 / Q000096:biosynthesis*; D004715:Endometriosis / Q000188:drug therapy / Q000378:metabolism*; D004717:Endometrium / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D007436:Intrauterine Devices, Medicated; D016912:Levonorgestrel / Q000627:therapeutic use; D008525:Medroxyprogesterone / Q000627:therapeutic use; D011374:Progesterone / Q000494:pharmacology / Q000627:therapeutic use*; D011372:Progestins / Q000627:therapeutic use*; D016211:Transforming Growth Factor alpha / Q000494:pharmacology
chemical_list: C483024:CCL5 protein, human; D018946:Chemokine CCL5; D011372:Progestins; D016211:Transforming Growth Factor alpha; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D016912:Levonorgestrel; D008525:Medroxyprogesterone